Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 28Carcinoma, Hepatocellular 25Colorectal Neoplasms 23Carcinoma, Non-Small-Cell Lung 13Melanoma 12Stomach Neoplasms 10Colonic Neoplasms 10Liver Neoplasms 9Neoplasm Metastasis 8Squamous Cell Carcinoma of Head and Neck 7Carcinoma, Transitional Cell 7Carcinoma, Renal Cell 7Uterine Cervical Neoplasms 6Rectal Neoplasms 6Ovarian Neoplasms 6Diabetes Mellitus, Insulin-Dependent, 12 6Prostatic Neoplasms 5Lung Neoplasms 5Gastrointestinal Stromal Tumors 5Esophageal Neoplasms 5Carcinoma 5Urinary Bladder Neoplasms 4Turcot syndrome 4Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Sarcoma 4Mesothelioma 4Endometrial Neoplasms 4Cholangiocarcinoma 4Carcinoma, Merkel Cell 4

Interventions

toripalimab 2Oxaliplatin 2tesetaxel 1indusatumab 1Trastuzumab 1S 1 (combination) 1Nivolumab 1Leucovorin 1Ipilimumab 1GC1118 1Fluorouracil 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of the Stomach × Ipilimumab × Gastrointestinal × Clear all
NCT03647969 2024-08-09

Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Completed
262 enrolled
Gastrointestinal

Adenocarcinoma of the Stomach

Data powered by HemOnc (CC BY 4.0) Colophon âš¡